Endocyte to Present at the Cowen and Company 38th Annual Health Care Conference
March 05 2018 - 4:01PM
Endocyte, Inc. (NASDAQ:ECYT), a biopharmaceutical company
developing targeted therapeutics for personalized cancer treatment
, today announced that the company’s management team will present
at the Cowen and Company 38th Annual Health Care Conference on
Monday, March 12th at 2:50 p.m. EDT.
A live audio webcast of the Company's presentation can be
accessed by visiting "Events & Presentations" under the
Investors & News section of Endocyte's website
at www.endocyte.com. The webcast will be archived shortly
after the live event, and a replay will be available on the
Company's website for 90 days following the conference.
About Endocyte
Endocyte is a biopharmaceutical company and leader in developing
targeted therapies for the personalized treatment of cancer. The
company's drug conjugation technology targets therapeutics and
companion imaging agents specifically to the site of diseased
cells. Endocyte's lead program is a prostate specific membrane
antigen (PSMA)-targeted radioligand therapy, 177Lu-PSMA-617,
entering Phase 3 for metastatic castration resistant prostate
cancer (mCRPC). Endocyte is also advancing its adaptor-controlled
CAR-T therapy into the clinic in 2018, where it will be studied in
osteosarcoma. For additional information, please visit Endocyte's
website at www.endocyte.com.
Investor Contact:Stephanie Ascher, Stern
Investor Relations, Inc., (212) 362-1200, stephanie@sternir.com
Endocyte, Inc. (delisted) (NASDAQ:ECYT)
Historical Stock Chart
From Sep 2024 to Oct 2024
Endocyte, Inc. (delisted) (NASDAQ:ECYT)
Historical Stock Chart
From Oct 2023 to Oct 2024